Zapata Quantum, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Zapata Quantum, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2024 | $3.88M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $5.68M | Dec 9, 2025 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2024 | $635.0K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $1.10M | Dec 9, 2025 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.34M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($38.14M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($29.73M) | Dec 9, 2025 |
| FY2023 | Dec 31, 2022 | $1.89M | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | ($10.9K) | Mar 22, 2023 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($3.43M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($23.05M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($18.11M) | Dec 9, 2025 |
| FY2023 | Dec 31, 2022 | ($1.51M) | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | ($10.9K) | Mar 22, 2023 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $252.0K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $4.42M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $5.92M | Dec 9, 2025 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.67M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($18.11M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($14.76M) | Dec 9, 2025 |
| FY2023 | Dec 31, 2022 | ($1.93M) | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | ($7.9K) | Mar 22, 2023 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2024 | $34.0K | Mar 31, 2026 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.27M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $2.73M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $8.07M | Dec 9, 2025 |
| FY2023 | Dec 31, 2022 | $240.38M | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | $597.6K | Mar 22, 2023 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.54M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $26.21M | Mar 31, 2026 |
| FY2025 | Feb 9, 2024 | $8.16M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $18.29M | Dec 9, 2025 |
| FY2023 | Dec 31, 2022 | $8.33M | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | $583.5K | Mar 22, 2023 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($8.27M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($23.47M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2023 | ($10.23M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2022 | ($57.08M) | Dec 9, 2025 |
| FY2023 | Dec 31, 2021 | $14.1K | Mar 26, 2024 |
| FY2022 | Jan 19, 2021 | $0 | Mar 22, 2023 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($118.33M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($127.67M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($89.53M) | Dec 9, 2025 |
| FY2023 | Dec 31, 2022 | ($7.09M) | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | ($10.9K) | Mar 22, 2023 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $38.0K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $2.69M | Dec 9, 2025 |
| FY2023 | Dec 31, 2022 | $0 | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | $0 | Mar 22, 2023 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2024 | $2.55M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $8.90M | Dec 9, 2025 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | (5) | Dec 9, 2025 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | (5) | Dec 9, 2025 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 172.32M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 43.59M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 4.68M | Dec 9, 2025 |